CO7151487A2 - Formulación de anticuerpos - Google Patents

Formulación de anticuerpos

Info

Publication number
CO7151487A2
CO7151487A2 CO14278419A CO14278419A CO7151487A2 CO 7151487 A2 CO7151487 A2 CO 7151487A2 CO 14278419 A CO14278419 A CO 14278419A CO 14278419 A CO14278419 A CO 14278419A CO 7151487 A2 CO7151487 A2 CO 7151487A2
Authority
CO
Colombia
Prior art keywords
antibody formulation
antibody
sugars
formulated
surfactant
Prior art date
Application number
CO14278419A
Other languages
English (en)
Inventor
Marta Cosenza
Christoph Stark
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48914378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7151487(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO7151487A2 publication Critical patent/CO7151487A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los anticuerpos anti-BAFFR se formulan como formulación líquida que comprende una alta concentración del ingrediente activo de anticuerpo para la entrega en un paciente sin altos niveles de agregación de anticuerpos. La composición farmacéutica acuosa puede incluir uno o más azúcares, un agente amortiguador, un surfactante, y/o un aminoácido libre.
CO14278419A 2012-06-12 2014-12-18 Formulación de anticuerpos CO7151487A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261658472P 2012-06-12 2012-06-12

Publications (1)

Publication Number Publication Date
CO7151487A2 true CO7151487A2 (es) 2014-12-29

Family

ID=48914378

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14278419A CO7151487A2 (es) 2012-06-12 2014-12-18 Formulación de anticuerpos

Country Status (36)

Country Link
US (4) US9216219B2 (es)
EP (2) EP3593814A1 (es)
JP (1) JP6265978B2 (es)
KR (1) KR102124820B1 (es)
CN (1) CN104363920B (es)
AR (1) AR091413A1 (es)
AU (1) AU2013276112B2 (es)
BR (1) BR112014030820B1 (es)
CA (1) CA2875386C (es)
CL (1) CL2014003370A1 (es)
CO (1) CO7151487A2 (es)
CY (1) CY1122181T1 (es)
DK (1) DK2858671T3 (es)
EA (1) EA033373B1 (es)
EC (1) ECSP15017314A (es)
ES (1) ES2751659T3 (es)
GT (1) GT201400285A (es)
HK (1) HK1203146A1 (es)
HR (1) HRP20191827T1 (es)
HU (1) HUE045523T2 (es)
IL (1) IL235966B (es)
LT (1) LT2858671T (es)
MA (1) MA37616A1 (es)
MX (1) MX363380B (es)
MY (1) MY179818A (es)
NZ (1) NZ630885A (es)
PE (1) PE20150200A1 (es)
PH (1) PH12014502778B1 (es)
PL (1) PL2858671T3 (es)
PT (1) PT2858671T (es)
SG (1) SG11201408174UA (es)
SI (1) SI2858671T1 (es)
TN (1) TN2014000488A1 (es)
TW (1) TWI653983B (es)
WO (1) WO2013186700A1 (es)
ZA (1) ZA201408547B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168591A1 (en) 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
KR20150132473A (ko) 2013-03-15 2015-11-25 다이액스 코포레이션 항-혈장 칼리크레인 항체
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN104730237A (zh) * 2013-12-23 2015-06-24 国家纳米科学中心 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法
JP6728053B2 (ja) 2014-03-12 2020-07-22 プロセナ バイオサイエンシーズ リミテッド 抗ｍｃａｍ抗体及び関連する使用方法
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
KR101597037B1 (ko) 2014-06-26 2016-02-24 엘지디스플레이 주식회사 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3916020A1 (en) * 2015-03-30 2021-12-01 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017046776A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
PT3386541T (pt) * 2015-12-07 2020-10-12 Merck Patent Gmbh Formulação farmacêutica aquosa compreendendo o anticorpo anti-pd-1 avelumab
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
TWI787161B (zh) * 2015-12-18 2022-12-21 日商安斯泰來製藥股份有限公司 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物
MA45381A (fr) * 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
EP3529269A2 (en) 2016-10-19 2019-08-28 Invenra, Inc. Antibody constructs
BR112019013107A2 (pt) 2016-12-22 2019-12-17 Univ Degli Studi Magna Graecia Catanzaro anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos
WO2018158332A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Formulations of monoclonal antibodies
BR112019018401A2 (pt) * 2017-03-06 2020-04-07 Merck Patent Gmbh formulação aquosa de anticorpo anti-pd-l1
US11639391B2 (en) * 2017-04-18 2023-05-02 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
JP7079844B2 (ja) 2017-07-27 2022-06-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 高濃度抗ｃ５抗体製剤
IL272773B2 (en) * 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
EP3717512A4 (en) * 2017-11-29 2021-08-25 Prothena Biosciences Limited LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETINE
CA3102349A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
EP3897714A1 (en) * 2018-12-18 2021-10-27 Novartis AG Protein solution formulation containing high concentration of an anti-vegf antibody
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
WO2020173431A2 (zh) * 2019-02-26 2020-09-03 信达生物制药(苏州)有限公司 包含抗cd47抗体的制剂及其制备方法和用途
JP2023501781A (ja) 2019-11-06 2023-01-19 ノバルティス アーゲー シェーグレン症候群の処置
WO2021136274A1 (zh) * 2019-12-30 2021-07-08 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
AU2021211799A1 (en) * 2020-01-21 2022-08-11 Innovent Biologics (Suzhou) Co., Ltd. Recombinant fully human anti-TIGIT monoclonal antibody preparations, preparation method therefor and use thereof
WO2022031567A1 (en) 2020-08-04 2022-02-10 Novartis Ag Treatment of b cell malignancies
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
CA3215919A1 (en) 2021-05-04 2022-11-10 Novartis Ag Treatment for systemic lupus erythematosus using anti-baffr antibodies
CA3216063A1 (en) 2021-05-04 2022-11-10 Novartis Ag Treatment for lupus nephritis using anti-baffr antibodies
AU2022354054A1 (en) * 2021-09-29 2024-03-28 Dragonfly Therapeutics, Inc. Antibodies targeting baff-r and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
AU780468B2 (en) 1999-06-23 2005-03-24 Oregon Health And Science University Method for enhancing hematopoiesis
PT1522590E (pt) 2000-06-28 2009-10-26 Glycofi Inc Métodos para a produção de glicoproteínas modificadas
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
EP1946776B1 (en) 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EA200701211A1 (ru) * 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
HUE025778T2 (en) 2008-07-17 2016-05-30 Novartis Ag Preparations and methods for the use of therapeutic antibodies
UA108994C2 (uk) * 2009-11-17 2015-07-10 Ипсен Фарма С.А.С. Фармацевтична композиція, що містить комбінацію hgh і rhigf-1, і процес її приготування (варіанти)
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation

Also Published As

Publication number Publication date
PH12014502778A1 (en) 2015-02-02
CA2875386C (en) 2022-09-13
MX2014015262A (es) 2015-06-23
US20180251564A1 (en) 2018-09-06
HUE045523T2 (hu) 2020-01-28
MX363380B (es) 2019-03-21
BR112014030820B1 (pt) 2023-02-07
SG11201408174UA (en) 2015-01-29
IL235966B (en) 2020-05-31
US20160145341A1 (en) 2016-05-26
GT201400285A (es) 2015-10-15
SI2858671T1 (sl) 2019-11-29
US20180051092A1 (en) 2018-02-22
PT2858671T (pt) 2019-10-28
CN104363920A (zh) 2015-02-18
US10689451B2 (en) 2020-06-23
AU2013276112A1 (en) 2014-12-18
KR102124820B1 (ko) 2020-06-22
EP3593814A1 (en) 2020-01-15
AR091413A1 (es) 2015-02-04
HRP20191827T1 (hr) 2019-12-27
ES2751659T3 (es) 2020-04-01
WO2013186700A1 (en) 2013-12-19
CN104363920B (zh) 2018-05-04
ZA201408547B (en) 2015-12-23
TW201402144A (zh) 2014-01-16
TWI653983B (zh) 2019-03-21
HK1203146A1 (en) 2015-10-23
LT2858671T (lt) 2019-10-25
DK2858671T3 (da) 2019-10-21
BR112014030820A2 (pt) 2017-07-25
PH12014502778B1 (en) 2015-02-02
MA37616A1 (fr) 2017-08-31
PL2858671T3 (pl) 2020-01-31
CY1122181T1 (el) 2020-11-25
EA033373B1 (ru) 2019-10-31
ECSP15017314A (es) 2018-06-30
US20130344088A1 (en) 2013-12-26
US9216219B2 (en) 2015-12-22
TN2014000488A1 (en) 2016-03-30
MY179818A (en) 2020-11-16
CL2014003370A1 (es) 2015-02-06
KR20150029683A (ko) 2015-03-18
EP2858671B1 (en) 2019-07-24
EP2858671A1 (en) 2015-04-15
IL235966A0 (en) 2015-01-29
JP2015521593A (ja) 2015-07-30
EA201492292A1 (ru) 2015-04-30
JP6265978B2 (ja) 2018-01-24
US9751951B2 (en) 2017-09-05
PE20150200A1 (es) 2015-02-08
CA2875386A1 (en) 2013-12-19
NZ630885A (en) 2016-01-29
AU2013276112B2 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
CO7151487A2 (es) Formulación de anticuerpos
CO7111300A2 (es) Formulación de anticuerpos
GT201700096A (es) Formulación estable de proteína en solución que contiene una alta concentración de un anticuerpo anti-vegf
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
WO2012076670A3 (en) Antibody formulation
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
AR098168A1 (es) Formulación estable de insulina glulisina
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
CO2017007316A2 (es) Formulación farmacéutica
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
CO6640306A2 (es) Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso
ECSP15005163A (es) Composiciones líquidas orales pediátricas que contienen nepadutant
PE20150022A1 (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
CL2015001970A1 (es) Una formulación liquida para el cuidado oral que comprende una mezcla de terpenos como principio activo
DOP2012000097A (es) Dispositivo multidosificador para administrar una dosis a paciente
CR11588A (es) Formulaciones farmacéuticas semisólidas